Insights

Brazilian Superior Court sets precedent on health plan coverage for cannabidiol-based medicines

On October 14, 2026, the Second Section of Brazil’s Superior Court of Justice (STJ) unanimously established a binding legal precedent regarding the obligation of private health insurance operators to cover cannabidiol-based medicines intended for home use.

The ruling marked the first time the STJ applied its new procedure for recognizing the relevance of a federal legal issue while simultaneously reaffirming settled case law and establishing a qualified precedent under Regulatory Amendment No. 55/2026.

Under the legal position established by the Court, private health insurance operators are generally not required to cover cannabidiol-based medicines for home use when there is no statutory or contractual obligation to do so, except where coverage is expressly required by legislation or applicable regulatory rules.

The STJ also clarified that an exceptional import authorization granted by Brazil’s National Health Surveillance Agency (Anvisa) does not, by itself, expand the scope of a health insurance contract or create a coverage obligation.

Regulatory authorization and health insurance coverage are separate issues

One of the central aspects of the decision is the distinction between regulatory authorization to import or use a medicine and the legal obligation of a private health insurance operator to pay for that treatment.

According to the STJ, an exceptional authorization issued by Anvisa may address regulatory issues associated with the absence of a formal marketing authorization. However, such authorization does not change the home-use nature of the medicine or automatically place it within the categories of mandatory health insurance coverage.

Coverage must therefore be assessed under Brazil’s private health insurance legislation, applicable regulatory standards and valid contractual provisions.

In particular, Article 10(VI) of Law No. 9,656/1998 permits the exclusion of medicines intended for home treatment, subject to statutory and regulatory exceptions.

What does the decision mean for health insurance operators?

The creation of a qualified precedent is expected to increase consistency in court decisions involving requests for coverage of cannabidiol-based medicines intended for home use.

For health insurance operators, the ruling provides greater legal predictability, but it should not be interpreted as authorization for automatic denials.

Each request should still be assessed individually, including:

  • whether the medicine is intended for home use;
  • whether the contract provides for coverage;
  • whether applicable legislation creates a specific obligation;
  • whether regulations issued by the National Supplementary Health Agency (ANS) apply;
  • whether the treatment falls within a statutory or regulatory exception;
  • whether the reasoning provided to the insured is consistent with the specific circumstances.

Medical prescription does not automatically determine coverage

The ruling also highlights the distinction between clinical necessity and the legal or contractual obligation to fund treatment.

A medical prescription remains relevant to the therapeutic decision, but does not, on its own, resolve the coverage issue.

Similarly, regulatory authorization from Anvisa does not replace the assessment required under the legal framework governing private health insurance.

In practice, a coverage request may require separate consideration of:

  1. clinical indication;
  2. regulatory status of the product;
  3. method and place of administration;
  4. contractual coverage;
  5. ANS regulations;
  6. statutory exceptions.

This distinction is particularly relevant in Brazil, where healthcare litigation continues to generate significant legal and economic impacts.

Recommended compliance measures

Private health insurance companies should consider reviewing their internal procedures in light of the precedent.

Relevant measures may include:

Reviewing internal coverage criteria

Policies for assessing home-use medicines should reflect current legislation, regulations and the legal position established by the STJ.

Strengthening the reasoning behind coverage decisions

Denial notices should clearly identify the contractual, statutory and regulatory grounds applicable to the individual request.

Reviewing contractual provisions

Clauses concerning medicines and home treatment should be assessed against applicable law and regulatory requirements.

Training multidisciplinary teams

Legal, regulatory, medical and customer service teams should understand the distinction between regulatory authorization, medical prescription and mandatory insurance coverage.

Reassessing litigation exposure

Existing disputes involving cannabidiol-based medicines should be reviewed in light of the new qualified precedent and the specific facts of each case.

Exceptions remain relevant

The STJ’s position does not establish an absolute prohibition on coverage of cannabidiol-based medicines.

The precedent expressly preserves situations in which coverage is required by law, contract or applicable regulation.

As a result, health insurance operators and insured individuals should avoid applying the decision mechanically to situations that may involve materially different legal circumstances.

A relevant development in Brazilian precedent-setting

The ruling is also significant from a procedural perspective.

It was the first case in which the STJ recognized the relevance of a federal legal issue, reaffirmed its existing case law and established a qualified precedent within the same proceeding under the summary procedure introduced by Regulatory Amendment No. 55/2026.

The precedent is expected to guide lower courts in cases falling within its scope, making accurate legal classification increasingly important for both litigation strategy and risk management.

PDK Advogados monitors regulatory and judicial developments affecting Brazil’s healthcare and supplementary health sectors, with particular attention to their legal and business implications.

Follow PDK Advogados’ publications for further analysis of Brazilian healthcare regulation, court precedents and their impact on businesses.

Conteúdo relacionado

New requirements increase sender traceability and provide for the blocking of unregistered corporate messages

Ruling addresses default notification in repossession proceedings involving fiduciary security

Maria Luísa Souza of PDK Advogados Recognized in Best Lawyers: Ones to Watch in Brazil 2027

MENU